Radiation Oncology, Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
Head Neck. 2011 Feb;33(2):286-8. doi: 10.1002/hed.21299.
Head and neck cutaneous squamous cell carcinoma (SCC) metastatic to lymph nodes is commonly treated with surgery plus radiotherapy.
We present the case of a 92-year-old man with cutaneous SCC metastatic to the neck (7 cm) who was treated with primary cetuximab and has had a durable complete response for 7 months. Because of his age, comorbidities, and unresectable neck lymphadenopathy, he received primary cetuximab. He received a 400 mg/m(2) loading dose and a 250 mg/m(2) weekly dose for 3 months and then had to discontinue as a result of other unrelated medical issues.
The patient had a complete response by 6 weeks. Seven months after discontinuing cetuximab, he continues to have a complete response.
Primary cetuximab for cutaneous SCC metastatic to lymph nodes is an area that bears further investigation because of its apparent efficacy and excellent toxicity profile.
头颈部皮肤鳞状细胞癌（SCC）转移至淋巴结，通常采用手术加放疗治疗。
我们报告了一例 92 岁皮肤 SCC 转移至颈部（7 厘米）的患者，他接受了西妥昔单抗的初始治疗，并且已经完全缓解 7 个月。由于年龄、合并症和不可切除的颈部淋巴结病，他接受了初始西妥昔单抗治疗。他接受了 400 mg/m(2)的负荷剂量和 250 mg/m(2)的每周剂量，持续 3 个月，但由于其他无关的医疗问题，不得不停药。
患者在 6 周时完全缓解。停止使用西妥昔单抗 7 个月后，他仍然完全缓解。
对于转移性至淋巴结的皮肤 SCC，初始西妥昔单抗治疗具有明显的疗效和良好的毒性特征，这是一个值得进一步研究的领域。
